Predicta Biosciences is a technology company.
Predicta Biosciences has raised $28.0M across 2 funding rounds.
Predicta Biosciences has raised $28.0M in total across 2 funding rounds.
Predicta Biosciences has raised $28.0M in total across 2 funding rounds.
Predicta Biosciences's investors include BlueStone Venture Partners, The Engine, Ulu Ventures.
Predicta Biosciences is a precision oncology company founded in 2023 that develops diagnostic and therapeutic products using multi-omics technology and liquid biopsies for non-invasive cancer testing, primarily targeting multiple myeloma and other blood cancers.[1][2][3][4] Its flagship product, GenoPredicta, is a Laboratory Developed Test (LDT) launched in April 2025 that analyzes whole genome sequencing (WGS) from blood or bone marrow to detect genomic alterations, stratify risk, and guide personalized treatments like CAR-T and bispecific antibodies, outperforming traditional FISH assays.[1][2][3][4] The company serves oncologists, patients, and healthcare providers by solving limitations in early detection and treatment optimization for incurable blood cancers and autoimmune diseases, with $28.6M raised to date—including a $23.4M round in October 2025—and strong growth via partnerships with Dana-Farber, academic centers, and groups like HealthTree Foundation.[1][2]
Predicta Biosciences emerged in 2023 from Harvard's Blavatnik Life Lab Longwood, founded by leading academics and clinicians from Harvard Medical School, MIT, Dana-Farber Cancer Institute, and the Broad Institute, including co-founders Irene Ghobrial, MD (multiple myeloma expert) and Kenneth C. Anderson, MD (cancer genomics specialist).[1][3][4] These physician-scientists, who treat patients daily, identified gaps in non-invasive diagnostics for blood cancers like multiple myeloma, where early detection and precise therapy selection remain challenging despite advances in immunotherapies.[2][3] Early traction came from research use of GenoPredicta at Dana-Farber, leading to its commercial LDT launch in April 2025 and a pivotal $23.4M funding round in October 2025, which appointed Brian McKernan as CEO to drive scaling.[1][2]
Predicta stands out in precision oncology through these key strengths:
Predicta rides the precision oncology wave, fueled by exploding demand for non-invasive diagnostics amid CAR-T, bispecifics, and personalized immunotherapies for blood cancers, where traditional tools fail to match therapeutic precision.[2][3] Timing is ideal post-2025 LDT launch, as regulatory shifts favor WGS-based tests and multi-omics data explodes, addressing a $10B+ market gap in multiple myeloma (no cure, poor early detection).[1][2] Market forces like aging populations, rising autoimmune cases, and AI integration amplify this, positioning Predicta to influence the ecosystem by feeding its database into drug discovery, partnering with pharma, and setting standards for liquid biopsy in hematologic malignancies.[1][3]
Predicta is poised for explosive growth, scaling its CLIA lab, commercializing GenoPredicta expansions, and launching autoimmune tests with $23.4M fuel and McKernan's leadership.[2] Trends like AI-multiomics convergence and immunotherapy dominance will propel its database into a therapeutics powerhouse, potentially yielding novel targets amid pharma's scramble for blood cancer assets.[1][3] Its influence could evolve from diagnostics leader to ecosystem shaper, humanizing precision oncology for patients long underserved by outdated tools—transforming "Predicta Biosciences is a technology company" into the understatement of biotech's next decade.
Predicta Biosciences has raised $28.0M across 2 funding rounds. Most recently, it raised $23.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $23.0M Series A | BlueStone Venture Partners, The Engine, Ulu Ventures | |
| Jul 1, 2024 | $5.0M Seed | BlueStone Venture Partners, The Engine, Ulu Ventures |